What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA
Romano Danesi, Yuk Ming Dennis Lo, Michael Oellerich, Julia Beck, Silvia Galbiati, Marzia Del Re, Evi Lianidou, Michael Neumaier, Ron H. N. van Schaik
Abstract
The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in kidney or heart transplant patients. The proper use of this technique is important, and starts with considering pre-analytic aspects. The current paper addresses some important technical considerations to ensure the proper and harmonized use of cfDNA techniques.
Topics & Concepts
WorkgroupMinimal residual diseaseMedicineCell-free fetal DNAOncologyCirculating tumor DNADiagnostic testInternal medicineComputational biologyComputer scienceCancerBiologyGeneticsEmergency medicineLeukemiaFetusComputer networkPregnancyPrenatal diagnosisCancer Genomics and DiagnosticsPancreatic and Hepatic Oncology ResearchRenal cell carcinoma treatment